| Catalog No. | HB038046 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG |
|---|
| Clone ID | MDX-1401 |
|---|
| Biological activity |
MDX-1401 binds to recombinant CD30 with a K d value of 0.83 nmol/L, exhibiting binding affinity comparable to that of its parental antibody MDX-060 [1]. MDX-1401 (125 I-MDX-1401) binds to CD30 on the surface of the Hodgkin's lymphoma cell line L540 cells, with a K d value of approximately 1.9 nmol/L [1]. MDX-1401 (0.012-50 ug/mL; 30 min primary incubation, 30 min secondary incubation) binds to CD30 + lymphoma cell lines (L540, Karpas-299, L428, L1236) in a dose-dependent manner, and its binding properties are consistent with those of the parental antibody MDX-060 [1]. MDX-1401 mediates FcγRIIIa-dependent antibody-dependent cellular cytotoxicity (ADCC) against L540 Hodgkin lymphoma cells, with an EC 50 of 0.009 ug/mL and a maximum cell lysis rate of 87%, exhibiting superior potency and efficacy compared to the parental antibody MDX-060 [1]. MDX-1401 (treated at 37°C for 4 h) mediates dose-dependent ADCC against CD30 + lymphoma cell lines (L540, Karpas-299, L428, L1236), with EC 50 values ranging from 0.008 to 0.04 ug/mL and maximum lysis rates of 13% to 68%. This includes activity against L1236 cells with low CD30 expression, against which the parental antibody MDX-060 shows no activity [1]. MDX-1401 binds to CD30 on L540 Hodgkin lymphoma cells with a K D value of 1.9 nM, and its antigen-binding affinity is nearly identical to that of its parental antibody MDX-060 (K D ~1.4 nM) [2]. MDX-1401 mediates significantly stronger and more effective ADCC against CD30-expressing tumor cell lines (including those with low CD30 expression) across all FcgRIIIa polymorphic variants, with a decreased EC 50 and an increased maximum specific lysis rate compared to its parental antibody [2]. MDX-1401 (1 mg/kg; i.p.; single dose) significantly prolongs the survival of SCID mice with systemic Karpas-299 ALCL [1]. |
| Expression system |
Mammalian cells |
| Clonality |
Monoclonal |
| Target |
CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P28908 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | MDX-1401, MDX1401, MDX1401 |
|---|
| Background | Tumor necrosis factor receptor superfamily member 8 (CD30/TNFRSF8) is a ~63 kDa protein. Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. CD30 is the therapeutic target of brentuximab vedotin (Adcetris). 2. Aizawa, S. et al. (1997) The Journal of biological chemistry 272, 2042-5. PMID: 8999898 |
|---|
| References |
1. Cardarelli PM, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res. 2009;15(10):3376-3383. [HB038046]
2. Cardarelli P M, et al. Characterization of MDX-1401, a Human Anti-CD30 Antibody with Enhanced Effector Function, for Therapy of Malignant Lymphoma[J]. Blood, 2008, 112(11): 1580. [HB038046]
3. Foyil KV, et al. Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep. 2010;5(3):140-147. [HB038046] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
